Research across kidney, bladder, and prostate cancers was showcased January 25-27 in San Francisco, California.
The Genitourinary Cancers Symposium took place Thursday, January 25, 2024, to Saturday, January 27, 2024, in San Francisco, California. Posters and presentations revealed the latest updates across kidney, bladder, and prostate cancer research.
Immunotherapy took center stage, with findings from the phase 3 AMBASSADOR Alliance A031501 (NCT03244384) and KEYNOTE-564 (NCT03142334) trials. Findings from a phase 2 trial (NCT03012321) of olaparib (Lynparza) plus abiraterone (Zytiga) and prednisone in metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 or ATM alterations were also highly anticipated.
Here are some of the highlights from the 3-day event.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More